Archives

19 August 2020 ASX ANNOUNCEMENT Head of Europe Appointed Medical Developments International (ASX: MVP) is pleased to announce the appointment of Mr Stefaan Schatteman as Head of its European business effective immediately. Stefaan will lead the Company’s direct push into the 27 member states in the EU and Switzerland. Stefaan is a 15-year veteran of […]

19 August 2020 ASX ANNOUNCEMENT Medical Developments to take control of EU markets Medical Developments International (ASX: MVP) today announced it has reached in principle agreement to enter into a contract with the Mundipharma network in Europe to take back the distribution rights for its pain relief drug, Penthrox® in all 27 member states in […]

26 May 2020 ASX ANNOUNCEMENT Appointment of Non-Executive Director – Christine Emmanuel Medical Developments International Limited (ASX: MVP) is pleased to announce the appointment of Christine Emmanuel as a Non-Executive Director of the Company with immediate effect. Christine has a Bachelor of Science and major in Economics (Hons: Chem) from Monash University, Certificate in Intellectual […]

25 May 2020 ASX Announcement Penthrox approved in Hungary Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Hungary.  The Marketing Authorisation issued by the National Institute of Pharmacy and Nutrition (OGYÉI), is for Penthrox® to be used for emergency relief of moderate to severe pain in […]

5 May 2020 ASX Announcement Penthrox approved in The Netherlands and Bosnia & Herzegovina. Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in The Netherlands and Bosnia & Herzegovina.  The Marketing Authorisation issued by the Medicines Evaluation Board of the Netherlands and the Agency for Medicinal […]

28 April 2020 ASX Announcement Penthrox is approved in Thailand Medical Developments International Limited (ASX: MVP), announce today that Penthrox® has been granted Market Authorisation in the Kingdom of Thailand. The Marketing Authorisation issued by the Thailand Food and Drug Administration (TFDA), is for Penthrox® to be used for Emergency relief of moderate to severe […]

19 February 2020 ASX ANNOUNCEMENT MVP has today released its FY20 Half Year Report and Accounts. Please refer to the following link for a copy – MVP FY20 Half Year Report  

6 December 2019 ASX ANNOUNCEMENT Penthrox Marketing Authorisation Application in Russia Medical Developments International Limited (ASX: MVP) announced today that the Russian Ministry of Health has accepted MVP’s Marketing Authorisation Application (MAA) for review. MVP submitted the MAA for Penthrox on 30 September and after a two-month validation period, the Russian Ministry of Health advised […]

21 November 2019 ASX ANNOUNCEMENT Penthrox IND approved in China Medical Developments International Limited (ASX: MVP) is delighted to announce the Chinese National Medical Product Administration (NMPA) has approved the opening of MVP?s Investigative New Drug (IND) application.? This application is a critical step and building block to having Penthrox approved for sale in China. […]

29 October 2019 ASX ANNOUNCEMENT MVP signs new Manufacturing Development Project with CSIRO Medical Developments International Limited (ASX: MVP) is delighted to announce it has signed an extension to the 2017 agreement with Australia?s national science agency, the Commonwealth Scientific and Industrial Research Organisation (CSIRO), to develop new manufacturing technologies for pharmaceutical products. This agreement […]